Altamira Therapeutics · Biologic · Phase 3
DiscontinuedTherapeutic
Population
Adults · ≥18 years
Severe acute unilateral SSNHL
Evidence
company
Confidence
95%
Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing Loss
Therapies database
Find a therapy. Follow the evidence.
See what is being studies, who is developing it, and how far it has progressed.
Search therapy records
Search a therapy, company, target, indication, or trial ID. Narrow by approach, stage, or status, then open a record to check its sources.
More filters and sort (2 active)
2 results
Altamira Therapeutics · Small Molecule · Phase 3
DiscontinuedTherapeutic
Population
Adults · 18–75 years
Acute post-injury tinnitus
Evidence
trial
Confidence
93%
Indications
Tinnitus
A listing is not proof of safety or effectiveness. Approval and availability may vary by indication and country.
How records are checked